title: Enhanced cellular immunity in macaques following a novel peptide immunotherapy.
abstract: Advances in treating and preventing AIDS depend on understanding how human immunodeficiency virus (HIV) is eliminated in vivo and on the manipulation of effective immune responses to HIV. During the development of assays quantifying the elimination of fluorescent autologous cells coated with overlapping 15-mer simian immunodeficiency virus (SIV) or HIV-1 peptides, we made a remarkable observation: the reinfusion of macaque peripheral blood mononuclear cells, or even whole blood, pulsed with SIV and/or HIV peptides generated sharply enhanced SIV- and HIV-1-specific T-cell immunity. Strong, broad CD4+- and CD8+-T-cell responses could be enhanced simultaneously against peptide pools spanning 87% of all SIV- and HIV-1-expressed proteins-highly desirable characteristics of HIV-specific immunity. De novo hepatitis C virus-specific CD4+- and CD8+-T-cell responses were generated in macaques by the same method. This simple technique holds promise for the immunotherapy of HIV and other chronic viral infections.
authors.affiliation: Department of Microbiology and Immunology, University of Melbourne, Victoria 3010, Australia.
authors.forename: S
authors.initials: S
authors.lastname: Chea
authors.forename: C J
authors.initials: CJ
authors.lastname: Dale
authors.forename: R
authors.initials: R
authors.lastname: De Rose
authors.forename: I A
authors.initials: IA
authors.lastname: Ramshaw
authors.forename: S J
authors.initials: SJ
authors.lastname: Kent
mesh_terms: D000818:Animals; D016913:Blood Component Transfusion; D001803:Blood Transfusion; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D004195:Disease Models, Animal; D006678:HIV / Q000276:immunology*; D015488:HIV Antigens / Q000008:administration & dosage / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D006526:Hepatitis C / Q000276:immunology; D018936:Hepatitis C Antigens / Q000008:administration & dosage / Q000276:immunology; D007167:Immunotherapy; D008254:Macaca nemestrina; D010455:Peptides / Q000008:administration & dosage / Q000276:immunology*; D012191:Retroviridae Proteins / Q000008:administration & dosage / Q000276:immunology; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000628:therapy*; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D015488:HIV Antigens; D018936:Hepatitis C Antigens; D010455:Peptides; D012191:Retroviridae Proteins
references.citation: Immunol Lett. 2001 Nov 1;79(1-2):57-61
references.pmid: 11595290
references.citation: J Immunol Methods. 2001 Sep 1;255(1-2):27-40
references.pmid: 11470284
references.citation: Nature. 2002 Jan 17;415(6869):331-5
references.pmid: 11797011
references.citation: Nature. 2002 May 2;417(6884):95-8
references.pmid: 11986671
references.citation: J Immunol. 2002 Jun 1;168(11):5954-8
references.pmid: 12023402
references.citation: Virology. 2002 Sep 15;301(1):176-87
references.pmid: 12359458
references.citation: J Immunother. 2002 Nov-Dec;25(6):500-8
references.pmid: 12439347
references.citation: Nat Med. 2003 Jan;9(1):27-32
references.pmid: 12496959
references.citation: Cancer Immunol Immunother. 2003 Jan;52(1):41-52
references.pmid: 12536239
references.citation: J Infect Dis. 2003 Jan 15;187(2):226-42
references.pmid: 12552447
references.citation: Eur J Immunol. 2003 Jun;33(6):1557-67
references.pmid: 12778473
references.citation: J Immunol Methods. 2003 Dec;283(1-2):141-53
references.pmid: 14659906
references.citation: J Virol. 1994 Jul;68(7):4650-5
references.pmid: 8207839
references.citation: J Virol. 1994 Sep;68(9):6103-10
references.pmid: 8057491
references.citation: J Immunol. 1997 Jan 15;158(2):807-15
references.pmid: 8992998
references.citation: Immunity. 1997 May;6(5):519-29
references.pmid: 9175830
references.citation: Science. 1997 Nov 21;278(5342):1447-50
references.pmid: 9367954
references.citation: J Virol. 1998 Dec;72(12):10180-8
references.pmid: 9811759
references.citation: J Immunol. 1998 Nov 15;161(10):5338-46
references.pmid: 9820507
references.citation: Science. 1999 Feb 5;283(5403):857-60
references.pmid: 9933172
references.citation: Clin Infect Dis. 1999 Mar;28(3):541-7
references.pmid: 10194075
references.citation: Science. 1999 Apr 30;284(5415):816-9
references.pmid: 10221916
references.citation: Nat Med. 1999 May;5(5):526-34
references.pmid: 10229229
references.citation: J Virol. 1999 Sep;73(9):7524-32
references.pmid: 10438842
references.citation: Vaccine. 2004 Nov 25;23(2):188-97
references.pmid: 15531036
references.citation: J Virol. 2004 Dec;78(24):13819-28
references.pmid: 15564490
references.citation: Immunol Rev. 1999 Aug;170:127-34
references.pmid: 10566147
references.citation: J Virol. 2000 Mar;74(6):2502-9
references.pmid: 10684264
references.citation: J Exp Med. 2000 May 1;191(9):1499-512
references.pmid: 10790425
references.citation: Nature. 2000 Sep 28;407(6803):523-6
references.pmid: 11029005
references.citation: Science. 2000 Oct 20;290(5491):486-92
references.pmid: 11039923
references.citation: J Virol. 2001 Feb;75(4):1990-5
references.pmid: 11160699
references.citation: Science. 2001 Apr 6;292(5514):69-74
references.pmid: 11393868
references.citation: Int Immunol. 2002 Jan;14(1):31-7
references.pmid: 11751749